Semaglutide (SEMA)

DRUG4 trials

Conditions

Atrial Fibrillation (AF)Bipolar Disorder (BD)Depression / Major Depressive DisorderDiabetes (DM)Nonalcoholic SteatohepatitisObesity (Disorder)SchizophreniaSevere Mental Illness

Phase 2

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

CompletedNCT04971785

Gilead SciencesNonalcoholic Steatohepatitis

Start: 2021-08-09End: 2024-12-09Updated: 2025-11-26

Phase 4

Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation

Not yet recruitingNCT07389941

University of LuebeckAtrial Fibrillation (AF)

Start: 2026-10-01End: 2029-04-01Target: 240Updated: 2026-02-11

Unknown Phase

Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes

Not yet recruitingNCT07424430

LMC Diabetes & Endocrinology Ltd.Diabetes (DM), Obesity (Disorder), Type 2 Diabetes

Start: 2026-03-01End: 2026-05-01Target: 400Updated: 2026-02-20

Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)

Not yet recruitingNCT07586150

Ludwig-Maximilians - University of MunichBipolar Disorder (BD), Depression / Major Depressive Disorder, Schizophrenia +1

Start: 2028-10-01End: 2030-12-01Target: 140Updated: 2026-05-14

Related Papers

Pharmacokinetics and Safety of Cilofexor and Firsocostat in Healthy Japanese and Non‐Japanese Participants

The Journal of Clinical Pharmacology2024-08-302 citations

Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.

2023-03-16314 citations

From cause to consequence: Insights into incident diabetes mellitus after hepatic steatosis

Clinical Liver Disease2023-01-132 citations